Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Preiss, D, Tobert, JA, Hovingh, GK, Reith, C
Natura:	Journal article
Lingua:	English
Pubblicazione:	Elsevier 2020

Documenti analoghi

Lipid-modifying agents, from statins to PCSK9 inhibitors
di: Preiss, D, et al.
Pubblicazione: (2020)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
di: Sanjiv Gupta
Pubblicazione: (2015-09-01)

United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8
di: Caleyachetty, R, et al.
Pubblicazione: (2021)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
di: K. O. Shnaider, et al.
Pubblicazione: (2023-12-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
di: Konstantinos Koskinas, et al.
Pubblicazione: (2016-07-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
di: Christopher LaFratte, et al.
Pubblicazione: (2023-09-01)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
di: Nissen, SE, et al.
Pubblicazione: (2016)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
di: Mohsin Haseeb, et al.
Pubblicazione: (2023-03-01)

JACC: Asia
di: Jian'an Wang, MD, PhD
Pubblicazione: (2021-06-01)

JACC: Asia
di: Valentin Fuster, MD, PhD, et al.
Pubblicazione: (2021-06-01)

The PCSK9 decade
di: Gilles Lambert, et al.
Pubblicazione: (2012-12-01)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
di: Mbikay Majambu, et al.
Pubblicazione: (2008-06-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
di: Shuai Wang, et al.
Pubblicazione: (2022-10-01)

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
di: Ying Xiao, et al.
Pubblicazione: (2022-11-01)

PCSK9 inhibitors
di: Baris Gencer, et al.
Pubblicazione: (2015-04-01)

JACC: Case Reports
di: Julia Grapsa, MD, PhD, et al.
Pubblicazione: (2019-08-01)

JACC: Case Reports
di: Julia Grapsa, MD, PhD, et al.
Pubblicazione: (2020-06-01)

JACC: Case Reports
di: Purvi Parwani, MBBS, MPH, et al.
Pubblicazione: (2020-09-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
di: Preiss, D, et al.
Pubblicazione: (2016)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
di: Maram H. Abduljabbar
Pubblicazione: (2024-11-01)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
di: Sliz, E, et al.
Pubblicazione: (2018)

Vision for JACC: Case Reports
di: Julia Grapsa, MD, PhD
Pubblicazione: (2019-06-01)

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week
di: Armitage, J, et al.
Pubblicazione: (2019)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
di: A. V. Blokhina, et al.
Pubblicazione: (2022-01-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
di: Markus Mohaupt
Pubblicazione: (2016-07-01)

PCSK9 Inhibitors: The Evolving Future
di: Bijay Mukesh Jeswani, et al.
Pubblicazione: (2024-11-01)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
di: Naoto Kuyama, et al.
Pubblicazione: (2021-06-01)

Introducing JACC: Basic to Translational Science
di: Douglas L. Mann, MD, et al.
Pubblicazione: (2016-01-01)

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient
di: Weiqi Zeng, et al.
Pubblicazione: (2023-08-01)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
di: Preiss, D, et al.
Pubblicazione: (2016)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
di: Dennis T. Ko, et al.
Pubblicazione: (2018-11-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
di: Tiny Nair
Pubblicazione: (2024-03-01)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
di: Martin Jozef Péč, et al.
Pubblicazione: (2023-08-01)

A Comprehensive Review of PCSK9 Inhibitors
di: Caroline Coppinger BS, et al.
Pubblicazione: (2022-05-01)

Cholesterol and stroke: role of PCSK9 inhibitors
di: L. Castilla-Guerra, et al.
Pubblicazione: (2019-04-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
di: A. Yu. Filatova, et al.
Pubblicazione: (2019-06-01)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
di: Marianna Puccini, et al.
Pubblicazione: (2022-03-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
di: Blom DJ, et al.
Pubblicazione: (2016-05-01)

Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
di: Zinan ZHAO, et al.
Pubblicazione: (2020-10-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
di: Lillian Smith, et al.
Pubblicazione: (2016-03-01)